The Utility of Pomalidomide in R/R Multiple Myeloma

Special Reports, B-Cell Malignancies, Volume 1, Issue 1

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

Manish Sharma, MD, from the Kimmel Cancer Center at Jefferson, comments on the use of pomalidomide in relapsed/refractory multiple myeloma.

In an updated analysis of the phase III MM-003 trial, Celgene International Sarl reported on a new progression-free survival analysis and final overall survival.Click here to read more > >